Cytokinetics | CYTK - Operating Profit


Cytokinetics reported $-179.17M in Operating Profit for its fiscal quarter ending in June of 2026.





Operating Profit Change Date
Acadia Pharmaceuticals USD 37.84M 42.45M Jun/2026
Amgen USD 4.61B 777M Jun/2026
Arca Biopharma USD -36.43M 2M Mar/2026
Bayer EUR 827M 2.7B Jun/2026
Biogen USD -243.8M 758.1M Jun/2026
Brainstorm Cell Therapeutics USD -2.05M 198K Mar/2026
Bristol-Myers Squibb USD 299M 3.07B Jun/2026
Capricor Therapeutics USD -29.16M 2.87M Dec/2025
Cytokinetics USD -179.17M 2.05M Jun/2026
Eisai JPY 24.73B 35.04B Jun/2026
Eli Lilly USD 12.46B 2.68B Jun/2026
Exelixis USD 248.41M 2.93M Jun/2026
Geron USD -236K 10.55M Mar/2026
Halozyme Therapeutics USD -63.72M 1.95M Jun/2026
Ionis Pharmaceuticals USD -102.29M 15.71M Jun/2026
Ligand Pharmaceuticals USD 56.62M 3.7M Jun/2026
Merck USD 840M 2.72B Jun/2026
Novartis USD 4.75B 515M Jun/2026
Pfizer USD 667M 4.32B Jun/2026
Regeneron Pharmaceuticals USD 1.42B 675.7M Jun/2026
Roche Holding CHF 11.46B 1.91B Jun/2026
Sanofi EUR 2.38B 449M Jun/2026